Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip Dubovsky

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
JAMA Network Open|April 26, 2023
Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical TrialGermán Áñez, Lisa M Dunkle, Cynthia L Gay, et al.
Medrxiv : the Preprint Server for Health Sciences|September 29, 2022
Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 TrialGermán Áñez, Lisa M Dunkle, Cynthia L Gay, et al.
The Lancet. Respiratory Medicine|November 20, 2021
Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trialSeth Toback, Eva Galiza, Catherine Cosgrove, et al.
Lancet (London, England)|December 13, 2005
Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trialPedro L Alonso, Jahit Sacarlal, John J Aponte, et al.
Trials|March 28, 2007
Evaluation of two formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years living in a malaria-endemic region of Mozambique: a Phase I/IIb randomized double-blind bridging trialEusebio V Macete, Jahit Sacarlal, John J Aponte, et al.
Vaccine|December 18, 2004
Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720Michael Walther, Susanna Dunachie, Sheila Keating, et al.
Lancet (London, England)|October 19, 2004
Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trialPedro L Alonso, Jahit Sacarlal, John J Aponte, et al.
Vaccine|January 26, 2006
A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CSSusanna J Dunachie, Michael Walther, Jenni M Vuola, et al.
Plos Clinical Trials|November 25, 2006
Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan childrenMark R Withers, Denise McKinney, Bernhards R Ogutu, et al.
Plos One|March 6, 2009
Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western KenyaBernhards R Ogutu, Odika J Apollo, Denise McKinney, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
JAMA Network Open|April 26, 2023
Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical TrialGermán Áñez, Lisa M Dunkle, Cynthia L Gay, et al.
Medrxiv : the Preprint Server for Health Sciences|September 29, 2022
Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 TrialGermán Áñez, Lisa M Dunkle, Cynthia L Gay, et al.
The Lancet. Respiratory Medicine|November 20, 2021
Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trialSeth Toback, Eva Galiza, Catherine Cosgrove, et al.
Lancet (London, England)|December 13, 2005
Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trialPedro L Alonso, Jahit Sacarlal, John J Aponte, et al.
Trials|March 28, 2007
Evaluation of two formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years living in a malaria-endemic region of Mozambique: a Phase I/IIb randomized double-blind bridging trialEusebio V Macete, Jahit Sacarlal, John J Aponte, et al.
Vaccine|December 18, 2004
Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720Michael Walther, Susanna Dunachie, Sheila Keating, et al.
Lancet (London, England)|October 19, 2004
Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trialPedro L Alonso, Jahit Sacarlal, John J Aponte, et al.
Vaccine|January 26, 2006
A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CSSusanna J Dunachie, Michael Walther, Jenni M Vuola, et al.
Plos Clinical Trials|November 25, 2006
Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan childrenMark R Withers, Denise McKinney, Bernhards R Ogutu, et al.
Plos One|March 6, 2009
Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western KenyaBernhards R Ogutu, Odika J Apollo, Denise McKinney, et al.
Pageof 6